Intravenous Amisulpride for the Prevention of Postoperative Nausea and Vomiting: Two Concurrent, Randomized, Double-blind, Placebo-controlled Trials

• Published in: Anesthesiology (Philadelphia) Vol. 126; no. 2; pp. 268 - 275
• Main Authors: Gan, Tong J, Kranke, Peter, Minkowitz, Harold S, Bergese, Sergio D, Motsch, Johann, Eberhart, Leopold, Leiman, David G, Melson, Timothy I, Chassard, Dominique, Kovac, Anthony L, Candiotti, Keith A, Fox, Gabriel, Diemunsch, Pierre
• Format: Journal Article
• Language: English
• Published: United States Copyright by , the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc 01.02.2017
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Dopamine Antagonists - administration & dosage; Dopamine Antagonists - therapeutic use; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle Aged; Postoperative Nausea and Vomiting - prevention & control; Sulpiride - administration & dosage; Sulpiride - analogs & derivatives; Sulpiride - therapeutic use; Treatment Outcome; Young Adult
• ISSN: 0003-3022; 1528-1175
• DOI: 10.1097/ALN.0000000000001458

BACKGROUND:Two essentially identical, randomized, double-blind, placebo-controlled, parallel-group phase III studies evaluated the efficacy of intravenous amisulpride, a dopamine D2/D3 antagonist, in the prevention of postoperative nausea and vomiting in adult surgical patients. METHODS:Adult inpatients undergoing elective surgery during general anesthesia and having at least two of the four Apfel risk factors for postoperative nausea and vomiting were enrolled at 9 U.S. and 10 European sites. A single 5-mg dose of amisulpride or matching placebo was given at induction of anesthesia. The primary endpoint was complete response, defined as no vomiting/retching and no use of antiemetic rescue medication in the 24-h postoperative period. Nausea incidence was a secondary endpoint. RESULTS:Across the two studies, 689 patients were randomized and dosed with study medication, of whom 626 were evaluable per protocol. In the U.S. study, 46.9% (95% CI, 39.0 to 54.9) of patients achieved complete response in the amisulpride group compared to 33.8% (95% CI, 26.2 to 42.0) in the placebo group (P = 0.026). In the European study, complete response rates were 57.4% (95% CI, 49.2 to 65.3) for amisulpride and 46.6% (95% CI, 38.8 to 54.6) for placebo (P = 0.070). Nausea occurred less often in patients who received amisulpride than those who received placebo. There was no clinically significant difference in the safety profile of amisulpride and placebo; in particular, there were no differences in terms of QT prolongation, extrapyramidal side effects, or sedation. CONCLUSIONS:One of the two trials demonstrated superiority, while pooling both in a post hoc change to the plan of analysis supported the hypothesis that amisulpride was safe and superior to placebo in reducing the incidence of postoperative nausea and vomiting in a population of adult inpatients at moderate to high risk of postoperative nausea and vomiting.